Risperidone in Children with Autism and Serious Behavioral Problems
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with autistic disorder who have serious behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic agents in children are limited. METHODS: We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old. The primary outcome measures were the score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions - Improvement (CGI-I) scale at eight weeks. RESULTS: A total of 101 children (82 boys and 19 girls; mean [+/-SD] age, 8.8+/-2.7 years) were randomly assigned to receive risperidone (49 children) or placebo (52). Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001). The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the CGI-I scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of 52, P<0.001). Risperidone therapy was associated with an average weight gain of 2.7+/-2.9 kg, as compared with 0.8+/-2.2 kg with placebo (P<0.001). Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison). In two thirds of the children with a positive response to risperidone at eight weeks (23 of 34), the benefit was maintained at six months. CONCLUSIONS: Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder. The short period of this trial limits inferences about adverse effects such as tardive dyskinesia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Methylphenidate, atomoxetine and guanfacine are beneficial for ADHD symptoms in ASD (Table 2 204 -206 )”
From Autism spectrum disorder (2020) · cites this paper as [206]
In the citing paper
“Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: risperidone [23] and aripiprazole [24]. Both drugs are approved for the treatment of irritability in children and adolescents with ASD.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“as the two drugs that have received FDA approval for use in ASD, risperidone, and aripiprazole, are both for the indication of “irritability” [23, 24]”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“risperidone and aripiprazole, which are both FDA-approved for irritability in children and adolescents with ASD [23, 24].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“and significant improvement in core autism symptoms [601-604].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [601]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Pervasive Developmental Disorders in preschool children
Chakrabarti, S. (2001) · JAMA · doi:10.1001/jama.285.24.3093 · Cited by 1,132
Gibbons, R. D. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210073009 · Cited by 719
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.633 · Cited by 427
Self-citationDiagnosing Autism: Analyses of Data from the Autism Diagnostic Interview
Lord, C., Pickles, A., McLennan, J., Rutter, M., Bregman, J., Folstein, S., Fombonne, E., Leboyer, M., & Minshew, N. (1997) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025873925661 · Cited by 373
The Vineland Adaptive Behavior Scales: Supplementary Norms for Individuals with Autism
Carter, A. S., Volkmar, F. R., Sparrow, S. S., Wang, J.-J., Lord, C., Dawson, G., Fombonne, E., Loveland, K., Mesibov, G., & Schopler, E. (1998) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1026056518470 · Cited by 367
Self-citation
Cited by
Items 801–900 of 1,000
Risperidone in pervasive developmental disorders
Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.6.713 · Cited by 18
Self-citationOccurrence of Priapism with Risperidone–Paroxetine Combination in an Autistic Child
Yang, P., & Tsai, J. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546042389127 · Cited by 16
Autism Spectrum Disorders in Early Childhood: An Overview for Practicing Physicians
Carr, J. E., & Leblanc, L. A. (2007) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2007.04.009 · Cited by 18
“At 6 months, most participants demonstrated sustained benefits [81] and minor improvements in adaptive behavior [82], although the core features of autism remained unchanged [83].”
BackgroundMahatmya, D., Zobel, A., & Valdovinos, M. G. (2008) · Journal of Early and Intensive Behavior Intervention · doi:10.1037/h0100413 · Cited by 17
“And unlike the other drugs, risperidone tends to target severe cases of SIB (McCracken et al., 2002).”
BackgroundPharmacology and Genetics of Autism: Implications for Diagnosis and Treatment
Brkanac, Z., Raskind, W. H., & King, B. H. (2008) · Personalized Medicine · doi:10.2217/17410541.5.6.599 · Cited by 20
An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Aishworiya, R., Valica, T., Hagerman, R. J., & Restrepo, B. (2024) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.24022006 · Cited by 19
Available Treatments for Autism Spectrum Disorder: From Old Strategies to New Options
Dell’Osso, L., Bonelli, C., Giovannoni, F., Poli, F., Anastasio, L., Cerofolini, G., Nardi, B., Cremone, I. M., Pini, S., & Carpita, B. (2025) · Pharmaceuticals · doi:10.3390/ph18030324 · Cited by 20
“Indeed, large, randomized trials on these drugs revealed a reduction in outbursts of anger, aggression, self-harm, and general regulation of disruptive behaviors [44,45,62,63,68].”
InfluentialEGGER, H. L. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2009.10.001 · Cited by 15
Cantin-Garside, K. D., Nussbaum, M. A., White, S. W., Kim, S., Kim, C. D., Fortes, D., & Valdez, R. S. (2020) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocaa169 · Cited by 17
“Such behaviors often fall under the umbrella term of self-injurious behavior (SIB).(3,4) SIB can include repetitive and rhythmic behaviors such as head banging and self-hitting,(5) and is a leading cause of hospitalization for children with ASD.”
BackgroundPaving Plant‐Food‐Derived Bioactives as Effective Therapeutic Agents in Autism Spectrum Disorder
Martins, N. A., Quispe, C., Kırkın, C., Şenol, E., Zuluğ, A., Özçelik, B., Ademiluyi, A. O., Oyeniran, O. H., Semwal, P., Kumar, M., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/1131280 · Cited by 17
Elnaiem, W., Benmelouka, A. Y., Elgendy, A. M. N., Abdelgalil, M. S., Alsaman, M. Z. B., Mogheeth, A., Ali, M. M. A., & Yousof, S. M. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2841 · Cited by 19
Deb, S. S., Bertelli, M. O., & Rossi, M. (2022) · Springer eBooks · doi:10.1007/978-3-319-95720-3_11 · Cited by 16
Lack of Dopaminergic Modulation of Cognitive Flexibility
Smyth, S. F., & Beversdorf, D. Q. (2007) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0b013e31815e6244 · Cited by 15
Douglas-Hall, P., Curran, S. R., Bird, V., & Taylor, D. M. (2011) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s4140 · Cited by 16
Coury, D. L., Swedo, S. E., Thurm, A. E., Miller, D. T., Veenstra-VanderWeele, J. M., Carbone, P. S., & Taylor, J. L. (2014) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2013.12.002 · Cited by 20
Recognition and treatment of mood dysregulation in adults with intellectual disability
Noel, J. M. (2018) · Mental Health Clinician · doi:10.9740/mhc.2018.11.264 · Cited by 16
Caldwell, M. F., Malterer, M. B., Umstead, D., & McCormick, D. J. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0013 · Cited by 15
Singappuli, P., Sonuga-Barke, E. J. S., & Kyriakopoulos, M. (2021) · CNS Spectrums · doi:10.1017/s1092852921000523 · Cited by 15
Using pharmacotherapy to address sleep disturbances in autism spectrum disorders
Mammarella, V., Orecchio, S., Cameli, N., Occhipinti, S., Marcucci, L., Meo, G. D., Innocenti, A., Ferri, R., & Bruni, O. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2267761 · Cited by 13
“Most studies regarding the effects of antipsychotics on sleep in patients with autism have focused exclusively on atypical agents, which block postsynaptic serotonin receptors and histamine H1 receptors too, thus reducing the risk of developing extrapyramidal side effects [69,70].”
BackgroundTeixeira, A. L. S., Bezerra, O. S., Rohde, L. A., & Graeff‐Martins, A. S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241241384 · Cited by 14
“However, they demonstrate considerable therapeutic resistance, with rates of approximately 30% for risperidone and 50% for aripiprazole, underscoring the difficulty in securing effective pharmacotherapy outcomes (McCracken et al., 2002; Owen et al., 2009).”
BackgroundMolecular Pathways, Neural Circuits and Emerging Therapies for Self-Injurious Behaviour
Zhang, K., Ibrahim, G. M., & Gouveia, F. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051938 · Cited by 17
“For instance, risperidone has significantly reduced irritability and aggression, with an 8-week, placebo-controlled trial reporting a 56.9% reduction in symptoms compared to 14.1% in the placebo group [196,197].”
InfluentialPharmacological Management in Children and Adolescents with Pervasive Developmental Disorder
Sung, M., Fung, D. S. S., Cai, Y., & Ooi, Y. P. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048670903493330 · Cited by 16
Endocannabinoid System Unlocks the Puzzle of Autism Treatment via Microglia
Su, T., Yan, Y., Li, Q., Ye, J., & Pei, L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.734837 · Cited by 41
“Long-term use of these drugs may cause some side effects, including sedation and weight gain (2).”
BackgroundFaja, S., Sabatos‐DeVito, M., Sridhar, A., Kuhn, J., Nikolaeva, J. I., Sugar, C. A., Webb, S. J., Bernier, R., Sikich, L., Hellemann, G., et al. (2023) · Autism Research · doi:10.1002/aur.2905 · Cited by 15
“Instruments (see Table 1) were selected from well-standardized clinician-administered and caregiver-completed measures based on their common use in clinical research and trials in ASD (Duifhuis et al., 2017; Locke et al., 2014; McCracken et al., 2002; Melamed et al., 2018; Owen et al., 2009; Parker et al., 2019; Scahi…”
BackgroundMethodAutism Spectrum Disorders: Comorbid Psychopathology and Treatment
Mohiuddin, S. S., Bobak, S., Gih, D. E., & Ghaziuddin, M. (2011) · Springer eBooks · doi:10.1007/978-1-4419-8065-6_29 · Cited by 19
“(McCracken et al., 2002).”
Karam, R. A., Rezk, N. A., Abdelrahman, H. M., Hassan, T., Mohammad, D., Hashim, H. M., & Fattah, N. R. A. (2013) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2013.04.002 · Cited by 19
Glutamatergic agents in Autism Spectrum Disorders: Current trends
Canitano, R., & Scandurra, V. (2014) · Research in Autism · doi:10.1016/j.rasd.2013.12.009 · Cited by 14
Cochrane Review: Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Williams, K. J., Wheeler, D. M., Silove, N., & Hazell, P. (2011) · Evidence-Based Child Health A Cochrane Review Journal · doi:10.1002/ebch.804 · Cited by 15
Low Dose Loxapine: Neuromotor Side Effects and Tolerability in Autism Spectrum Disorders
Hellings, J. A., Jadhav, M., Jain, S., Jadhav, S., & Genovese, A. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0145 · Cited by 14
“…ar-ipiprazole are the only atypical antipsychotics shown to decrease such behaviors, including aggression, irritability, and self-injury, in large-scale, double-blind placebo-controlled studies in subjects with autistic disorder (McCracken et al. 2002; Marcus et al. 2011; Benvenuto et al. 2013).”
Correlates of weight gain during long-term risperidone treatment in children and adolescents
Calarge, C. A., Nicol, G. E., Xie, D., & Zimmerman, B. M. (2012) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-6-21 · Cited by 18
“Short-term randomized pediatric trials in disruptive behavior, bipolar, psychotic, tic, and pervasive developmental disorders have all revealed a somewhat comparable weight gain with AAPs [22,36,61-64].”
BackgroundDrug Class Review: Atypical Antipsychotic Drugs
McDonagh, M. S., Peterson, K., Carson, S., Fu, R., & Thakurta, S. (2010) · Cited by 16
Behavioral Problems in Fragile X Syndrome: A Review of Clinical Management
Davidson, M., Sebastian, S. A., Benitez, Y., Desai, S., Quinonez, J., Ruxmohan, S., Stein, J. D., & Cueva, W. (2022) · Cureus · doi:10.7759/cureus.21840 · Cited by 22
“FDA approval of risperidone in treating aggression and self-injury in children with ASD was achieved in 2006 [16,24].”
BackgroundMcPartland, J. C., & Klin, A. (2006) · PubMed · doi:10.1016/j.admecli.2006.06.010 · Cited by 56
Scott, L. J., & Dhillon, S. (2008) · CNS Drugs · doi:10.2165/00023210-200822030-00006 · Cited by 14
Body mass index (BMI) in newly admitted child and adolescent psychiatric inpatients
Vieweg, W. V. R., Kuhnley, L. J., Kuhnley, E. J., Anum, E. A., Sood, B., Pandurangi, A. K., & Silverman, J. J. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.01.001 · Cited by 15
Eapen, V., & Gururaj, A. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0502 · Cited by 14
Approaches to Multisite Clinical Trials: The National Institute of Mental Health Perspective
Lebowitz, B. D., Vitiello, B., & NORQUIST, G. S. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006992 · Cited by 14
Self-citationPsychopharmacology in autism spectrum disorders
Kwok, H. W. M. (2003) · Current Opinion in Psychiatry · doi:10.1097/00001504-200309000-00007 · Cited by 14
APA Working Group on Psychoactive Medications for Children and Adolescents (2006) · PsycEXTRA Dataset · doi:10.1037/e539722009-001 · Cited by 14
Dysregulation in Children and Adolescents Presenting to a Multidisciplinary Autism Clinic
Vasa, R. A., Singh, V., McDonald, R. G., Mazefsky, C. A., Hong, J. S., & Keefer, A. J. (2021) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-021-05056-y · Cited by 15
Gao, N., Liu, Z., Wang, H., Shen, C., Dong, Z., Cui, W., Xiong, W., & Mei, L. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.0247-23.2023 · Cited by 14
2-Ethylhexanol induces autism-like neurobehavior and neurodevelopmental disorders in zebrafish
Eghan, K., Lee, S., Yoo, D., & Kim, W. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.137469 · Cited by 14
Tsujino, T., Isayama, H., Nakai, Y., Ito, Y., Togawa, O., Toda, N., Arizumi, T., Kogure, H., Yamamoto, K., Mizuno, S., et al. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0698-5 · Cited by 15
“Finally, the safety of risperidone has been established in patients with schizophrenia [20, 21].”
BackgroundCanitano, R. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.11.024 · Cited by 15
Brain Mechanisms of Plasticity in Response to Treatments for Core Deficits in Autism
Ventola, P. E., Oosting, D., Anderson, L. C., & Pelphrey, K. A. (2013) · Progress in brain research · doi:10.1016/b978-0-444-63327-9.00007-2 · Cited by 15
Yoshida, K., Koyama, E., Zai, C. C. H., Beitchman, J. H., Kennedy, J. L., Lunsky, Y., Desarkar, P., & Müller, D. J. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720971950 · Cited by 15
“It was reported that approximately 70% and 40% of patients in the 2 trials had intellectual disabilities.(68,76) Likewise, Anderson et al.”
BackgroundAssessing and treating aggression in children and adolescents
Adesanya, D. O., Johnson, J. L., & Galanter, C. A. (2021) · Pediatric Medicine · doi:10.21037/pm-20-109 · Cited by 19
“McCracken 2002, (72) ASD Multisite, randomized, double-blind trial 5–17 years RISP effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior”
BackgroundShurtz, L., Schwartz, C., DiStefano, C., McPartland, J. C., Levin, A. R., Dawson, G., Kleinhans, N. M., Faja, S., Webb, S. J., Shic, F., et al. (2022) · Autism · doi:10.1177/13623613221121425 · Cited by 13
“…antipsychotics (risperidone and ariprazole) for the indication of irritability (Accordino et al., 2016; Alfageh et al., 2020; Fallah et al., 2019; McCracken et al., 2002; Marcus et al., 2009), but children with ASD are prescribed psychotropic medications widely, as evidenced by the ATN data…”
BackgroundGupta, N., & Gupta, M. (2023) · CNS Spectrums · doi:10.1017/s1092852923002389 · Cited by 18
“44,45 Risperidone at a mean dose of 1.8 mg/ day was found to be safe and effective for irritability.”
BackgroundInfluentialWake, R., Miyaoka, T., Inagaki, T., Furuya, M., Ieda, M., Liaury, K., Kishi, K., & Horiguchi, J. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0108 · Cited by 14
A Review of Empirical Evidence of Somatic Treatment Options for the MI/DD Population
Ulzen, T., & Powers, R. E. (2008) · Psychiatric Quarterly · doi:10.1007/s11126-008-9077-z · Cited by 14
Current practice in psychopharmacology for children and adolescents with autism spectrum disorders
Floyd, E. F., & McIntosh, D. E. (2009) · Psychology in the Schools · doi:10.1002/pits.20431 · Cited by 13
Unwanted Interactions Among Psychotropic Drugs and Other Treatments for Autism Spectrum Disorders
Theoharides, T. C., & Asadi, S. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825e00e4 · Cited by 13
Prescribing antipsychotics for children and adolescents
James, A. C. (2010) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.108.005652 · Cited by 14
Lundwall, R. A., Stephenson, K. G., Tass, E. S., Cox, J. C., South, M., Bigler, E. D., Anderberg, E., Prigge, M. B. D., Hansen, B. D., Lainhart, J. E., et al. (2016) · Research in Autism · doi:10.1016/j.rasd.2016.12.001 · Cited by 15
“Following McCracken et al. (2002) among others, scores <18 are Low Aggression (ASDLA) and scores ≥18 are High Aggression (ASDHA).”
BackgroundFreitag, C. M., & Jarczok, T. A. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1501-5_13 · Cited by 13
Erdoğan, A., Karaman, M. G., Özdemir, E., Yurteri, N., Tufan, A. E., & Kurçer, M. A. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0113 · Cited by 13
An Update on Publicly Funded Multisite Trials in Pediatric Psychopharmacology
Vitiello, B. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.010 · Cited by 14
Self-citationCarlson, G. A., Althoff, R. R., & Singh, M. K. (2024) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2024.2332999 · Cited by 12
“The primary condition, autism, is not the focus of treatment (e.g. McCracken et al., 2002).”
BackgroundClozapine Treatment for Aggressive Behaviors in Youths with Neurodevelopmental Disorders
Berloffa, S., Masi, G., Falcone, F., Simonelli, V., Narzisi, A., Valente, E., Viglione, V., Milone, A., & Sesso, G. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2023.0097 · Cited by 13
“Risperidone and aripiprazole have been approved by the U.S. Food and Drug Administration (FDA) to treat irritability in this population (McCracken et al., 2002; Owen et al., 2009).”
Doyle, C. A., McDougle, C. J., & Stigler, K. A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0506-5_9 · Cited by 13
Self-citationLoxapine Treatment in an Autistic Child with Aggressive Behavior: Therapeutic Challenges
Reinblatt, S. P., Abanilla, P. K., Jummani, R. R., & Coffey, B. J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.639 · Cited by 12
“D ESPITE EVIDENCE SUPPORTING autistic children (McCracken et al. 2002), these medications have been increasingly associated with a risk of adverse events such as obesity, diabetes, hyperlipidemia and metabolic syndrome (Allison et al., 1999; Arana, 2000; Lieberman III 2004; Nasrallah and Newcomer…”
Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes
Correll, C. U. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.3.foc368 · Cited by 12
Gender Differences in Treatment-Seeking Youth with Autism Spectrum Disorder
Cariveau, T., McCracken, C., Bradshaw, J. L., Postorino, V., Shillingsburg, M. A., McDougle, C. J., Aman, M. G., McCracken, J. T., Tierney, E., Johnson, C. R., et al. (2021) · Journal of Child and Family Studies · doi:10.1007/s10826-021-01905-7 · Cited by 15
Self-citationMyers, S. M., & Challman, T. D. (2018) · American Academy of PediatricsItasca, IL eBooks · doi:10.1542/9781610021357-19 · Cited by 14
Gora, C., Dudas, A., Court, L., Annamneedi, A., Lefort, G., Nakahara, T. S., Azzopardi, N., Acquistapace, A., Lainé, A.-L., Trouillet, A., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03174-6 · Cited by 13
“Atypical antipsychotics, such as risperidone and aripiprazole, as well as antidepressants, target co-occurring irritability, self-injury, rituals, anxiety, and depression [8 – 10].”
Symptom scores and medication treatment patterns in children with ADHD versus autism
Mayes, S. D., Waxmonsky, J. G., Baweja, R. K., Mattison, R. E., Memon, H., Klein, M., Hameed, U., & Waschbusch, D. A. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112937 · Cited by 12
Pharmacological Treatment of Autism
Gibbs, T. T. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1272-5_15 · Cited by 13
Mental health problems in children and adolescents with intellectual disability
Gray, K. M., & Mohr, C. (2004) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000139971.60436.3c · Cited by 12
Oral glucose tolerance test in children and adolescents: Positives and pitfalls
Conwell, L. S., & Batch, J. (2004) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2004.00487.x · Cited by 12
Saxena, K., Chang, K., & Steiner, H. (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00334.x · Cited by 12
¿Podemos curar el autismo? Del desenlace clínico a la intervención
Alessandri, M., Thorp, D. M., Mundy, P. C., & Tuchman, R. F. (2005) · Revista de Neurología · doi:10.33588/rn.40s01.2004648 · Cited by 29
Gao, X., Xu, G., Fu, N., Ben, Q., Wang, L., & Bu, X. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1511920 · Cited by 21
Methylphenidate–risperidone combination in child psychiatry: A retrospective analysis of 44 cases
Javelot, H., Glay-Ribau, C., Ligier, F., Weiner, L., Didelot, N., Messaoudi, M., Socha, M., Lawson, F. B., & Kabuth, B. (2014) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2013.12.009 · Cited by 13
"The presentation and classification of anxiety in autism spectrum disorder": Commentary.
Scahill, L. (2012) · Clinical Psychology: Science and Practice · doi:10.1111/cpsp.12018 · Cited by 11
Self-citationCoghill, D. (2003) · Advances in Psychiatric Treatment · doi:10.1192/apt.9.4.289 · Cited by 13
Hassiotis, A., Melville, C. A., Jahoda, A. J., Strydom, A., Cooper, S., Taggart, L., Cooper, V., Steed, L., Ali, A., Hunter, R. M., et al. (2022) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2022.104202 · Cited by 13
The Absence of Caspase-8 in the Dopaminergic System Leads to Mild Autism-like Behavior
Suárez‐Pereira, I., García-Domínguez, I., Bravo, L., Santiago, M., García‐Revilla, J., Espinosa‐Oliva, A. M., Alonso-Bellido, I. M., López‐Martín, C., Pérez-Villegas, E. M., Armengol, J. A., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.839715 · Cited by 13
State of the Evidence for Use of Psychotropic Medications in School-Age Youth
Shahidullah, J. D., Roberts, H. J., Parkhurst, J. T., Ballard, R., Mautone, J. A., & Carlson, J. S. (2023) · Children · doi:10.3390/children10091454 · Cited by 16
“The seminal study supporting the efficacy of risperidone in ASD was the Research Units in Pediatric Psychopharmacology (RUPP) study which randomized 101 subjects aged 5–17 years to 8 weeks of risperidone (1.8 = 0.7 mg/day) or placebo [108].”
BackgroundInfluentialTeixeira, E. H., Jacintho, A. C. D. Á., Celeri, E. H. R. V., & Dalgalarrondo, P. (2013) · Trends in Psychiatry and Psychotherapy · doi:10.1590/s2237-60892013000300002 · Cited by 13
Current status of biological treatment options in Autism Spectrum Disorder
Eapen, V., Nicholls, L. E., Spagnol, V., & Mathew, N. E. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.07.025 · Cited by 12
“…effect sizes and high response rates, they have also demonstrated serious adverse effects, including dyslipidemia, hyperglycaemia and weight gain (McCracken et al., 2002; McDougle et al., 2005; Owen et al., 2009; Findling et al., 2014) necessitating careful monitoring and appropriate…”
BackgroundClinical Profile of Autism Spectrum Disorder in a Pediatric Population from Northern Mexico
González-Cortés, T., Gutiérrez-Contreras, E., Espino-Silva, P. K., Cruz, J. H.-S., Álvarez-Cruz, D., Rosales-González, C. C., Sida-Godoy, C., Nava-Hernández, M. P., López-Márquez, F. C., & Ruíz-Flores, P. (2019) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-019-04154-2 · Cited by 12
van Andel, D. M., Sprengers, J. J., Keijzer‐Veen, M. G., Schulp, A. J. A., Lillien, M. R., Scheepers, F. E., & Bruining, H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.780281 · Cited by 16
“In this study we selected the aberrant behavioral scale-irritability (ABC-I) as the primary endpoint as this might overlap with behavioral sensory tolerance, is a reasonable outcome measure to detect change and is a frequently used behavioral scale in various NDD trials making it suitable for cross-disorder trial desi…”
MethodClinical Approach in Autism: Management and Treatment
Riesgo, R. D. S., Gottfried, C., & Becker, M. M. (2013) · InTech eBooks · doi:10.5772/54784 · Cited by 14
Talero‐Gutiérrez, C., Martínez, L. E., Ovalle, J. P., Velásquez-Torres, A., & Zarruk, J. G. (2024) · Revista Ciencias de la Salud · doi:10.12804/revistas.urosario.edu.co/revsalud/a.793 · Cited by 11
Recent developments and strategies in pediatric pharmacology research in the USA
Vitiello, B. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-36 · Cited by 11
Self-citationDemb, H. B., Valicenti-McDermott, M., Navarro, A., & Ayoob, K. T. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822befa9 · Cited by 11
An Open Trial of Olanzapine in Children and Adolescents With Asperger Disorder
Milin, R., SIMEON, J. G., Batth, S., Thatte, S., Dare, G. J., & Walker, S. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000196114.93376.86 · Cited by 11
Lobry, A., Jutard, C., Bodeau, N., Kloeckner, A., Consoli, A., & Cohen, D. (2011) · Adolescent Psychiatry · doi:10.2174/2210676611101020163 · Cited by 14
“…trials to date, risperidone (Aman, De Smedt, Derivan, Lyons & Finding, 2002; Buitelaar, Van der Gaag, Cohen-Kettenis & Melman, 2001; McCracken et al., 2002; Shea et al., 2004; Snyder, et al., 2002), aripiprazole (Marcus, et al., 2009; Owen, et al., 2009) and divalproex (Hollander…”
BackgroundAdvances in Pediatric Pharmacology, Therapeutics, and Toxicology
Berlin, C. M. (2001) · Advances in Pediatrics · doi:10.1016/s0065-3101(23)00086-5 · Cited by 11
Valdovinos, M. G., Zarcone, J. R., Hellings, J. A., Kim, G., & Schroeder, S. R. (2003) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2004.00583.x · Cited by 11
Kim, H., Park, E. J., Kim, J.-H., Boon‐yasidhi, V., Tarugsa, J., Reyes, A., Manalo, S. G., & Joung, Y. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0152 · Cited by 14
“Although risperidone has been shown to be effective for reducing behavioral symptoms and impulsivity in several studies (McCracken et al. 2002; Shea et al. 2004; Nagaraj et al. 2006; Aman et al. 2015; McGuire et al. 2016), the drug is associated with adverse effects (AEs) such as increased…”
Psychopharmaka im Kindes- und Jugendalter
Trott, G. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_57 · Cited by 12
Trouble hyperactif avec déficit de l'attention ou dysharmonie d'évolution ? Soyons sûrs…
Fourneret, P., Boutiere, C., & Revol, O. (2005) · Archives de Pédiatrie · doi:10.1016/j.arcped.2005.01.002 · Cited by 11
Summers, J., Houlding, C., & Reitzel, J.-A. (2004) · Focus on Autism and Other Developmental Disabilities · doi:10.1177/10883576040190020401 · Cited by 16
Interventions for Autism Spectrum Disorders: State of the evidence
(2009) · PsycEXTRA Dataset · doi:10.1037/e533422010-001 · Cited by 11
Gao, X., Fu, N., Ben, Q., & Bu, X. (2025) · Nutrition Reviews · doi:10.1093/nutrit/nuaf050 · Cited by 13
Kawamura, A., Fujii, K., Tamada, K., Abe, Y., Nitahara, K., Iwasaki, T., Yagishita, S., Tanaka, K. F., Takumi, T., Takao, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59853-5 · Cited by 12
Panda, P. K., Sharawat, I. K., Gupta, D., Palayullakandi, A., Sopanam, S., & Saha, S. (2025) · Brain and Development · doi:10.1016/j.braindev.2025.104454 · Cited by 12
Ameringen, M. V., Fineberg, N. A., Ravindran, A. V., Arnold, P. D., Beaulieu, S., Brakoulias, V., Brietzke, E. M., Dowlati, Y., Drummond, L. M., Ferretti, C. J., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.039 · Cited by 14
Metadata
- Authors
- McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08
- Volume
- 347
- Issue
- 5
- Pages
- 314-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1968430210
- Cited by
- 1,574
- References
- 25
- Citations by year
- 2026: 50 · 2025: 68 · 2024: 54 · 2023: 43 · 2022: 51 · 2021: 77 · 2020: 54 · 2019: 43 · 2018: 69 · 2017: 56 · 2016: 57 · 2015: 59 · 2014: 57 · 2013: 88 · 2012: 88
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institutes of Health (n01mh070009-000, n01mh070001-008, n01mh070010-001, n01mh080011-005)
- National Institute of Mental Health (N01-MH-80011, N01 MH 70010, K23MH001883, N01 MH-70001, N01 MH 70009)
- National Center for Research Resources (M01-RR 00750, M01 RR-00052, M01-RR-00034, M01RR000750, M01RR000052, M01RR000034)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- risperidone, autism spectrum disorder, atypical antipsychotics, irritability, tantrums, aggression, self-harm, Aberrant Behavior Checklist, weight gain, adverse effects, children
- MeSH terms
- Adolescent, Autistic Disorder, Child, Child Behavior, Child, Preschool, Double-Blind Method, Female, Humans, Male, Antipsychotic Agents, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.